Görüntüleme
19
İndirme
2
Lung cancer occurred in approximately 1,8 million patients and caused an estimated 1,6 million deaths in 2012, worldwide. NSCLC constitutes approximately 85% of all lung cancers. Patients with early-stage NSCLC are surgically treated for curative goals. However, many patients are at risk of recurrence despite complete resection. This suggests that a large proportion of patients have the micrometastatic disease even at the early course of the disease. In this review, we aimed to evaluate the results of adjuvant chemotherapy, targeted therapy and immunotherapy studies to improve survival in NSCLC.
Lung cancer occurred in approximately 1.8 million patients and caused an estimated 1.6 million deaths in 2012, worldwide. NSCLC constitutes approximately 85% of all lung cancers. Patients with early-stage NSCLC are surgically treated for healing purposes. However, many patients are at risk of recurrence despite complete resection. This suggests that a large proportion of patients have the micrometastatic disease even at the early course of the disease. In this review, we aimed to evaluate the results of adjuvant chemotherapy, targeted therapy and immunotherapy studies to improve survival in NSCLC.
Alan : Sağlık Bilimleri
Dergi Türü : Ulusal
Makale Detay 
Benzer Makaleler
Dergi Bilgisi
Eseri Dinleyin
Alıntı Yap
Bu Sayfayı Yazdırın
Paylaş
Mendeley
